Zevra Therapeutics is trading at $10.71, down 5.39%, with no fresh company-specific announcement or catalyst identified in available coverage to explain the October 13 decline. - The provided sector context reports XBI fell 2.01% during the session. - Recent reporting cites broader biotech headwinds, including rising rates and cautious investor sentiment. Sector weakness may have contributed but does not establish the cause of Zevra Therapeutics’ larger decline. - Trading volume information was unavailable.